loader2
Partner With Us NRI

Healthcare Global Enterprises Ltd share Price Today

Company details

382.25
395.95
310.00
401.00
6M Return 5.23%
1Y Return 22.31%
Mkt Cap.(Cr) 5,367.54
Volume 1,398,610
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 1,398,610

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Global Enterprises announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue: Rs 4,946 million 12% YoY
  • Adjusted EBITDA: Rs 941 million 21% YoY
  • PAT: Rs 213 million  154% YoY

FY24 Financial Highlights:

  • Revenue: Rs 19,121 million 13% YoY
  • Adjusted EBITDA: Rs 3,374 million 11% YoY
  • PAT: Rs 482 million 65% YoY

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “We experience a deep sense of fulfilment to report a consistent benchmark-beating performance across all fronts for the quarter and the fiscal year ending FY24. Year after year, HCG has achieved sustainable cancer care outcomes comparable to premier centers in the world, thanks to our unique value-based care model and focused factory approach providing patients with the right treatment at the right time, using best in class talent, knowledge, technology, and infrastructure.

Given the mounting incidence of cancer in recent years, India has prudently enhanced its cancer diagnosis and treatment processes in the guiding light of visionary crusaders like HCG. We prioritize a deep engagement in academics and research alongside an unflinching focus on patient outcomes. In the past year, we have made significant triumphs, including the successful completion if comprehensive genomic profiling for over 1,000 cancer patients, executing complex surgeries, and launching our all-in-one mobile application, among other feats.

Our extensive presence in 18 regions across nine states, with one-third of our centers located in tier-II and tier-III cities, underscores our sterling commitment of providing affordable and quality cancer care for every cancer patient across India. Our ability and agility to build heartfelt relationships with patients is built on a rock-solid foundation of compassion and trust, which truly sets us apart in this crucial sector. As we get ready to lock horns with new challenges and keep pace with the evolving paradigms of tomorrow, we earnestly resolve to make a bigger difference in the lives of patients, our most valued stakeholders.”

Raj Gore, CEO HealthCare Global Enterprises Ltd. added, “We are delighted to report that our revenues grew by 12% for Q4FY24 on YoY basis. Our Adjusted EBIDTA (excl. ESOP cost) for Q4FY24 stood at Rs 94 crore, a growth of 21% YoY, with margins standing at 19.0%, an increase of 140 bps compared to the same period last year.

Over the year, we have taken multiple steps to enhance our operations and improve our profitability. After consistently achieving organic growth for 3-4 years, we're now poised to expedite HCG's expansion through strategic acquisitions. In addition to our expansion efforts in Indore, we are committed to further strengthening our presence in Bangalore. We are currently in the process of establishing two hospitals with 125 beds in North Bangalore and White field area, slated to be operational within the next 12 to 15 months. These state-of-the-art facilities will enhance our capacity to cater to the growing cancer care needs of the region.

Alongside, to enhance the patient experience and streamline access to healthcare services, we have introduced the 'HCG CARE' smart app suite. This innovative platform provides patients with seamless access to their medical records and treatment information with just one click. The app would also help us consistently engage with patients post treatments, to continue monitor adherence to treatment and follow up to improve outcome. Already, the app has benefited over 56,000 outpatients, with active participation from 300 consulting doctors on the digital platform.

Our patient-centric vision continues to guide us in making a meaningful difference in the lives of those we serve by redefining healthcare through global innovation. We pledge to uphold our commitment to “Adding Life to Years” in the coming financial years as well.”

Result PDF

View Other Company Results

Healthcare Global Enterprises Ltd shares SWOT Analysis

Strengths (8)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (3)

  • Promoters increased pledged shares QoQ
  • Book Value Per Share deteriorating for last 2 years
  • High volume, top losers

Opportunity (2)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • RSI indicating price strength

Threats (3)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Companies Increasing Debt as per Annual Report

Resistance and support

R1 393.5
R2 401.6
R3 407.2
Pivot

387.85

S1 379.8
S2 374.2
S3 366.1
EMA SMA
368.5
363.2
360.5
352.9
364.4
364.2
359.3
361.4
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ACESO COMPANY PTE LTD Bulk Purchase 2023-06-01 320 3575000 NSE
B S AJAIKUMAR Bulk Sell 2023-06-01 320 3575000 NSE
ACESO COMPANY PTE LTD Block Purchase 2023-06-01 320 3575000 NSE
Name Category Shares
AJAIKUMAR B S PROMOTER 10.41%
ACESO COMPANY PTE. LTD. PROMOTER 60.4%

OUR RESEARCH VIEW

Investment recommendation
Expertise in cancer-care and expansion to the fore…
Call Date
18 Mar 2024
Entry Price 345.00
Target Price 435.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Healthcare Global Enterprises Ltd Stocks COMPARISON

Financials( in Cr) Healthcare Global Enterprises Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Global Health Ltd
Price 385.35 6,236.35 903.05 493.50 1,373.45
% Change -1.51 0.46 -2.68 -1.74 1.27
Mcap Cr 5,367.54 89,669.36 87,768.51 37,257.18 36,878.09
Revenue TTM Cr 1,691.41 16,612.50 4,831.37 6,537.06 2,694.25
Net Profit TTM Cr 17.63 887.50 1,103.51 632.98 326.08
PE TTM 115.87 99.87 82.94 63.47 77.03
1 Year Return 22.31 21.21 50.10 60.83 115.17
ROCE 6.56 14.16 13.85 7.51 16.49
ROE 1.35 15.04 16.12 6.79 16.13
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 860.53 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,550.52 645.34
LAST 3M 103,712.87 -29,605.88
LAST 6M 176,931.00 -14,371.69
LAST 12M 290,309.13 100,312.35

Healthcare Global Enterprises Ltd Information

Stock PE (TTM)
115.87
Promoter Holding
71.28%
Book Value
59.2851
ROCE
6.56%
ROE
1.35%
Description
  • Healthcare Global Enterprises Ltd is a provider of speciality healthcare in India focused on cancer and fertility. Under the `HCG` brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB. As of March 31, 2017, HCG network consisted of 18 comprehensive cancer centres, including its centre of excellence in Bengaluru, three freestanding diagnostic centres and one day care chemotherapy centre across India. Under the `Milann` brand, it operates fertility centres. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. The Milann network also operates on a model similar to our HCG network, wherein the various Milann fertility centres aim to provide medical services following established protocols with a focus on quality medical care across diagnosis and treatment. The company operates seven Milann fertility centres across Bengaluru, Delhi, Chandigarh and Mumbai as on March 31, 2017. Healthcare Global Enterprises operates two multi-speciality hospitals in Ahmedabad and Bhavnagar, both in the state of Gujarat. HCG Multispecialty in Ahmedabad and Bhavnagar are tertiary care hospitals with 118 and 39 available operational beds, respectively, as of March 31, 2017. It provides comprehensive inpatient and outpatient treatments. Its key specialties include cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary and critical care. Healthcare Global Enterprises provides clinical reference laboratory services in India under the Triesta brand with a specialisation in oncology, including molecular diagnostic services and genomic testing. It has Triesta central reference laboratory located in its centre of excellence in Bengaluru. The Triesta central reference laboratory is accredited by NABL in India, as well as by CAP for quality assurance of laboratory tests performed. Additionally, Triesta offers research and development services to pharmaceutical and biotechnology companies in the areas of clinical trial management and biomarker discovery and validation. Healthcare Global Enterprises Ltd was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited on November 14, 2005. Thereafter the company was converted into a public limited company and the name of the company was changed to HealthCare Global Enterprises Limited on July 5, 2006. The company acquired 50.10% equity interest in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare. HCG EKO Oncology LLP (HCG EKO LLP) HCG EKO LLP was incorporated on May 15, 2015, under the LLP Act as a limited liability partnership firm. HCG EKO LLP is authorised to primarily engage in the business of setting up hospitals at Kolkata with high end linear accelerators, oncology pharmacy and matters incidental and ancillary thereto. HCG (Mauritius) Pvt. Ltd. (HCG Mauritius) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Mauritius is authorised to hold companies which are primarily engaged in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology. HealthCare Global (Africa) Pvt. Ltd (HCG Africa) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Africa is authorised to engage in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology and hold companies which are engaged in the same business. Healthcare Global Enterprises entered into a share purchase agreement dated November 23, 2015 with HCG TVH, its erstwhile subsidiary, and Anderson Diagnostics Private Limited. Pursuant to the terms of this agreement, Healthcare Global Enterprises has transferred its entire shareholding in HCG TVH aggregating 51% of the total paid up equity share capital of HCG TVH to Anderson Diagnostics Private Limited for an aggregate consideration of Rs.510,000. Accordingly, HCG TVH has ceased to be the subsidiary of the Company during the Financial Year. During the financial year ended 31 March 2016, Healthcare Global Enterprises transferred its entire shareholding in HealthCare Global (Uganda) Private Limited (`HCG Uganda`), HealthCare Global (Kenya) Private Limited (`HCG Kenya`) and HealthCare Global (Tanzania) Private Limited (`HCG Tanzania`) to HealthCare Global (Africa) Pvt. Ltd. Accordingly, HCG Uganda, HCG Kenya and HCG Tanzania have become level two subsidiaries of the company. During the year under review, Healthcare Global Enterprises introduced two major latest technologies at some of its centres viz. Robotic Surgery and Tomotherapy Treatment System. Robotic Surgery is an advanced form of minimally invasive or laparoscopic (small incision) surgery, where surgeons use a computer-controlled robot to assist them in certain surgical procedures. This facility was installed at Bangalore and Ahmedabad centres. The TomoTherapy treatment system uses a patented multi-leaf collimator (MLC) that divides the radiation beam into beamlets, all aimed at the tumor. More beam directions give physicians more control in how they plan treatments-and more assurance that dose will be confined to the tumor, reducing the risk of short- and long-term side effects. This facility was installed at Kalinga Rao Road centre, Bangalore. During the financial year ended 31 March 2016, the company completed its Initial Public Offering (IPO) of 29,800,000 equity shares of Rs. 10 each, comprising of Fresh Issue of 11,600,000 equity shares and Offer For Sale of 18,200,000 equity shares at a premium of Rs. 208 per equity share. The total issue size was Rs. 6496.4 million. The IPO was open for subscription during the period from 16 to 18 March 2016. The shares got listed the National Stock Exchange of India Limited and BSE Limited on 30 March 2016. In April 2016, HCG launched its first cancer centre in Visakhapatnam, under its subsidiary company, HCG Pinnacle Oncology Private Limited. HCG Pinnacle Cancer Centre has a capacity of upto 88 beds and provides high quality and comprehensive cancer care services. In May 2016, the company launched its new advanced comprehensive cancer centre in Baroda, under its subsidiary, HCG Oncology LLP. The Centre has a bed capacity of 65 beds and is one of the most advanced in terms of technology in the HCG network. HCG Manavata Oncology LLP was incorporated on August 10, 2016, under The Limited Liability Partnership Act, 2008 as a limited liability partnership firm. The Partners of the LLP are HCG and Dr. Rajnish Nagarkar, in the capital contribution ratio of 51:49, respectively. HCG Manavata Oncology LLP is authorised to primarily engage in the business of setting up hospitals at Nashik, Maharashtra with high end linear accelerators, pharmacy and matters incidental and ancillary thereto. In March 2017, HCG expanded its operations in Nashik. HCG through its subsidiary HCG Kenya signed definitive agreements in March 2017 to acquire a majority stake in Cancer Care Kenya (CCK) a leading cancer care centre in Nairobi, Kenya, subject to review and approval by the Competition Authority of Kenya (CAK) and other requisite approvals. CDC, the development finance institution of UK Government, which has partnered with HCG for Africa investments, would partner with HCG through HCG Kenya, an off-shore subsidiary, for the acquisition. MP Shah Hospital, a leading tertiary care hospital in Kenya, will also participate in the transaction. CCK, which started operations in 2010, is the first comprehensive cancer centre in Kenya. CCK treats over a thousand patients annually including over two hundred patients from other African nations. During the year ended 31 March 207, the percentage of holding of Healthcare Global Enterprises Ltd in HCG NCHRI Oncology LLP increased from 51% to 76%.In May 2017, HCG launched its first cancer centre in Kanpur, the largest the state of Uttar Pradesh, under its subsidiary company, HCG Regency Oncology Healthcare Private Limited. HCG Regency Oncology Centre is equipped with 90 beds and features advanced radiation therapy, a multi-disciplinary team of oncologists including sub-specialists, as well as the first PET-CT and bone marrow transplant unit.

Registered Address

HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar, Bangalore, Karnataka, 560027

Tel : 91-80-4660-7700
Email : investors:hcgoncology.com; info:hcgoncology.com
Website : http://www.hcgel.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 539787
NSE Code : HCG
Book Closure Date (Month) :
BSE Group : B
ISIN : INE075I01017

FAQ’s on Healthcare Global Enterprises Ltd Shares

You can buy Healthcare Global Enterprises Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Healthcare Global Enterprises Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 18, 2024 03:55 PM the closing price of Healthcare Global Enterprises Ltd was Rs.385.35.

The latest PE ratio of Healthcare Global Enterprises Ltd as of Jun 18, 2024 03:55 PM is 115.87

The latest PB ratio of Healthcare Global Enterprises Ltd as of Jun 18, 2024 03:55 PM is 0.15

The 52-week high of Healthcare Global Enterprises Ltd share price is Rs. 401.00 while the 52-week low is Rs. 310.00

According to analyst recommendations, Healthcare Global Enterprises Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 18, 2024 03:55 PM, the market cap of Healthcare Global Enterprises Ltd stood at Rs. 5,367.54.

Download App

Download Our App

Play Store App Store
market app